Overall verdict
Neutral
5.7/10
1-year performance
+228.00%
Score breakdown
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
Hyperliquid Strategies Inc. operates as a digital asset treasury company in the United States. It focuses on building, managing, and optimizing HYPE tokens, which are the native digital assets of the Hyperliquid Layer-1 blockchain. The company is headquartered in New York, New York.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
David Schamis
Founded
2025
Employees
5
Revenue / employee
1.9M USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.3.97%
- STATE STREET CORP3.52%
- MORGAN STANLEY3.48%
- D1 Capital Partners L.P.2.48%
- Paradigm Operations LP2.24%
- BIT Capital GmbH2.23%
- Invesco Ltd.2.22%
- CITADEL ADVISORS LLC1.85%
- Nearwater Capital Markets, Ltd1.57%
- Other institutions22.56%
- Rest of the register53.86%
177 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
14.76 USD
52-week low
3.01 USD
1-year performance
228.00%
Rising
Year-to-date performance
294.90%
Rising
Drawdown
-11.99%
Mild pullback
Position in the 52-week range
85% of range
Range: 17.00 USD - 19.45 USD (2 methods agree)
Net margin 3358.6%, ROIC 33.9%, ROE 33.9%.
Net margin
3358.64%
Exceptional
Sector -15.62%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
33.94%
Exceptional
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
33.94%
Exceptional
Free cash flow margin (FCF)
-202.40%
Negative
Profit-to-cash conversion (FCF conversion)
-0.06x
Low
Revenue to net income
Revenue (trailing 12 months)
9.5M USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
4.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
20.0x
Fair
Sector 29.9x|S&P 23.0x
Forward P/E
26.5x
Fair
EV / EBITDA
—
N/A (loss)
Sector 23.3x|S&P 14.5x
PEG
—
Sector 0.13|S&P 0.86
Fair value (reverse DCF)
18.10 USD
Undervalued
Market cap
3.3Md USD
Financial strength
10.0/10no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-7.36%
Net cash
Cash
138M USD
Cash / market cap
4.16%
Tight
Net debt
-138M USD
Equity
1.9Md USD
Closed daily candles, 10 months
Last close on September 24, 2026: 14.09 USD
- MM2012.39
- MM509.43
- MM2006.71
- RSI 1466.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
50-day average slope, 1 month
+21.77%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
6.59 % per day
Volatility change
+3.80%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 0.49 (3) | 0.24 (2) | 50 (4) | — | 111 (3) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | PURR | 5.7 | 5.7 | 3.3Md USD | 20.0x | 3358.6 % | — | 33.9 % | — | -0.6 % | 228.0 % | ||
| 7 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 8 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
